Pharmacotherapies that increase CNS expression of heme oxygenase-1 (HO-1) and other antioxidant proteins have improved outcome in experimental models of spontaneous intracerebral hemorrhage (ICH). In order to more specifically investigate the relationship between HO-1 and ICH outcome, mice expressing human HO-1 driven by the glial fibrillary acidic protein (GFAP) promoter (GFAP·HMOX1 mice) were tested in a model of in situ parenchymal hemorrhage. Injection of collagenase into the striata of wild-type (WT) mice resulted in a 26.3% mortality rate, with deaths equally distributed between males and females. Mortality was reduced to 4.48% in GFAP·HMOX1 mice. Cell viability in the injected striata of surviving WT mice was reduced by about half at one week and was significantly increased in transgenics; this benefit persisted over a 22 day observation period. Cell counts guided by design-based stereology indicated loss of~40% of neurons in WT hemorrhagic striata at one week, which was decreased by half in transgenics; no significant differences in microglia or astrocyte numbers were observed. Blood-brain barrier disruption and short-term neurological deficits were also mitigated in GFAP·HMOX1 mice, but long-term outcome did not differ from that of WT survivors. These results suggest that astrocyte HO-1 overexpression provides robust neuroprotection after acute intracerebral hemorrhage. Further investigation of drug or genetic therapies that selectively increase astrocyte HO-1 is warranted.
Introduction
Spontaneous intracerebral hemorrhage (ICH) accounts for about 10% of strokes, and continues to have a grim prognosis despite improvements in neurointensive care (Rincon and Mayer, 2013) . One month mortality approximates 50%; recovery to independent living status is attained in only 20% of survivors (Broderick et al., 1999) , and the vast majority report poor health-related quality of life (Christensen et al., 2009; Delcourt et al., 2017) . The mechanisms mediating perihematomal cell loss have not been precisely defined, but considerable experimental evidence supports the participation of oxidative and inflammatory injury cascades that may be amenable to targeted pharmacotherapies. One promising target is heme oxygenase-1 (HO-1), which catalyzes the ratelimiting step of heme breakdown to carbon monoxide, iron and bilirubin. HO-1 robustly protects astrocytes from heme-mediated injury in vitro (Benvenisti-Zarom and Regan, 2007) , and may have beneficial effects on heme clearance in vivo (Parfenova et al., 2005; Schallner et al., 2015) . Conversely, an increase in the early inflammatory response has also been observed after ICH when expression is primarily localized to microglia and macrophages (Wang and Doré, 2007) .
HO-1 is minimally expressed in the CNS under physiological conditions, but it is induced by oxidative stress via Nrf2-regulated transcriptional activation. In rodents, systemic treatment with low molecular weight Nrf2 activators increased CNS HO-1, with expression localized most prominently to perivascular astrocytes (Alfieri et al., 2013; Jazwa et al., 2011; Yamauchi et al., 2004) . This treatment was sufficient to attenuate cell loss, blood-brain barrier breakdown, inflammation, and neurological deficits after ICH in wild-type (WT) mice, while Nrf2 knockout prevented any benefit and worsened injury (Iniaghe et al., 2015; King et al., 2011; Wang et al., 2007; Zhao et al., 2007) . However, since Nrf2 regulates the expression of multiple antioxidant and anti-inflammatory proteins, the relationship between HO-1 induction and protection cannot be precisely defined by these experiments.
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